引用本文:陈雨思,李 江.肺动脉高压靶向药物治疗现状和展望[J].中国临床新医学,2020,13(9):852-858.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 70次   下载 97 本文二维码信息
码上扫一扫!
分享到: 微信 更多
肺动脉高压靶向药物治疗现状和展望
陈雨思,李 江
410011 长沙,中南大学湘雅二医院心内科
摘要:
[摘要] 肺动脉高压(PAH)是一种高死亡率的肺血管疾病,其特征是肺血管重构和肺血管阻力增加,如果不及时治疗,最终导致右心衰竭和死亡。在过去的几十年中,靶向药物的出现显著改善了患者结局。但目前的治疗仍难以阻止或逆转PAH的病程进展,PAH仍然是一种致命性的疾病,为此开发新的药物治疗靶点尤为重要。目前,针对肺动脉平滑肌细胞异常增殖、迁移和凋亡的潜在逆转肺血管重构途径的药物正成为研究热点,为治愈PAH带来了新的希望。该文对PAH靶向药物的治疗现状和展望进行阐述,并讨论靶向治疗PAH的循证医学证据。
关键词:  肺动脉高压  靶向药物  治疗
DOI:10.3969/j.issn.1674-3806.2020.09.02
分类号:R 544.1+6
基金项目:国家自然科学基金资助项目(编号:81870233)
Current status and prospects of targeted drug therapy for pulmonary arterial hypertension
CHEN Yu-si, LI Jiang
Department of Cardiology, the Second Xiangya Hospital of Central South University, Changsha 410011, China
Abstract:
[Abstract] Pulmonary arterial hypertension(PAH) is a pulmonary vascular disease associated with high mortality and is characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance. If not treated in time, PAH will eventually lead to right ventricular failure and death. Over the past few decades, the emergence of targeted drugs has significantly improved the outcomes of the patients, but the current treatments are still difficult to halt or reverse the progression of PAH. PAH remains a fatal disease, making it particularly important to develop new targets for drug therapy. Currently, drugs targeting at potentially reversing pulmonary vascular remodeling caused by abnormal proliferation, migration and apoptosis of pulmonary artery smooth muscle cells are becoming a research hotspot, which brings new hope for curing PAH. In this paper, the current status and prospects of PAH targeted drugs treatment is reviewed, and the evidence-based medical evidence for PAH targeted treatment is discussed.
Key words:  Pulmonary arterial hypertension(PAH)  Targeted drugs  Treatment